Stimulant use among clients entering drug treatment in Europe

References

• CND. World situation with regard to drug trafficking. Commission on Narcotic Drugs, Economic and Social Council, New York 2009
   Google Scholar
• Council of the European Union (2001). Council resolution on the implementation of the five key epidemiological indicators on drugs, developed by the European monitoring centre for drugs and drug addiction. CORDROGUE, 67 of 15/11/2001
   Google Scholar
• Council of the European Union. Council recommendation of 18 June 2003 on the prevention and reduction of health-related harm associated with drug dependence. Official Journal of the European Union 2003; 165: 31–33
   Google Scholar
• Council of the European Union. Regulation (EC) no.1920/2006 of the European parliament and of the council of 12 December 2006 on the European monitoring centre for drugs and drug addiction (recast). Official Journal L 2006; 376(1)1–13
   Google Scholar
• Delas J, Adán E, Díaz O, Aguas M, Pons M, Fuertes R. Smoked cocaine in socially-depressed areas. Harm Reduction Journal 2010; 7: 27
   PubMed Web of Science ®Google Scholar
• EMCDDA (2010a). Annual report 2010: The state of the drugs problem in Europe. Luxembourg: Office for Official Publications of the European Union. Retrieved from http://www.emcdda.europa.eu/publications/annual-report/2010
   Google Scholar
• EMCDDA (2010b). Problem amphetamine and methamphetamine use in Europe: Selected Issue 2010. Luxembourg: Office for Official Publications of the European Union. Retrieved from http://www.emcdda.europa.eu//alias.cfm//publications/selected-issues/problem-amphetamine?
   Google Scholar
• EMCDDA (2010c). Treatment demand indicator (TDI). Lisbon: Author. Retrieved from http://www.emcdda.europa.eu/themes/key-indicators/tdi
   Google Scholar
• EMCDDA (2011a). Brief glossary of chemical and biochemical terms. Lisbon: Author. Retrieved from http://www.emcdda.europa.eu/publications/drug-profiles/glossary
   Google Scholar
• EMCDDA (2011b). Statistical Bulletin 2011. Luxembourg: Office for Official Publications of the European Union. Retrieved from http://www.emcdda.europa.eu/stats11/tdi
   Google Scholar
• Health Service Executive (2010). National Service Plan 2010. Dublin: Author. Retrieved from www.hse.ie/eng/services/Publications/corporate/serviceplan.pdf
   Google Scholar
• Huffman JC, Stern TA. Using psychostimulants to treat depression in the medically ill. Primary Care Companion to the Journal of Clinical Psychiatry 2004; 6: 44–46
   PubMedGoogle Scholar
• Iversen E, (2009). Coverage assessment of data collected in the framework of the EMCDDA treatment demand indicator. Final report. Lisbon: EMCDDA. Retrieved from http://www.emcdda.europa.eu/html.cfm/index67086EN.html
   Google Scholar
• Jenner L, & Saunders, J. (2004). Psychostimulant withdrawal and detoxification. In A. Baker, N.K. Lee, & L. Jenner (Eds.), Models of interventions and care of psychostimulant users (Monograph Series No. 52, pp. 35–50). Australia: Commonwealth of Australia
   Google Scholar
• Marshall BD, Wood E, Shoveller JA, Buxton JA, Montaner JS, Kerr T. Individual, social, and environmental factors associated with initiating methamphetamine injection: Implications for drug use and HIV prevention strategies. Prevention Science 2011; 12: 173–180
   PubMed Web of Science ®Google Scholar
• McCabe SE, Boyd CJ, Teter CJ. Medical use, illicit use, and diversion of abusable prescription drugs. Journal of American College Health 2006; 54: 269–278
   PubMed Web of Science ®Google Scholar
• Montanari L, Serafini M, Maffli E, Busch M, Kontogeorgiou K, Kuijpers W, , Gyarmathy VA, et al. Gender and regional differences in client characteristics among substance abuse treatment clients in the Europe. Drugs: Education, Prevention and Policy 2010; 18: 24–31
   Web of Science ®Google Scholar
• Moreno AY, Mayorov AV, Janda KD. Impact of distinct chemical structures for the development of a methamphetamine vaccine. Journal of the American Chemical Society 2011; 133: 6587–6595
   PubMed Web of Science ®Google Scholar
• NIDA. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry 2005; 58: 158–164
   PubMed Web of Science ®Google Scholar
• Nutt DJ, King LA, Phillips LD. Drug harms in the UK: A multicriteria decision analysis. Lancet 2010; 376: 1558–1565
   PubMed Web of Science ®Google Scholar
• Plan Nacional sobre Drogas (2007). Programa de actuación frente a la cocaína 2007–2010. Ministerio de Sanidad, Servicios Sociales e Igualdad (BOE de 24 de enero de 2012) la Delegación del Gobierno para el Plan Nacional sobre Drogas. Retrieved from http://www.pnsd.mspsi.es/Categoria2/publica/pdf/memo2007.pdf
   Google Scholar
• Prinzleve M, Haasen C, Zurhold H, Matali JL, Bruguera E, Gerevich J, , Krausz M, et al. Cocaine use in Europe – A multi-centre study: Patterns of use in different groups. European Addiction Research 2004; 10: 147–155
   PubMed Web of Science ®Google Scholar
• Roche A, McCabe S, Smyth B. Illicit methadone use and abuse in young people accessing treatment in opiate dependence. European Addiction Research 2011; 14: 219–225
   Web of Science ®Google Scholar
• Sanchez-Niubo A, Fortiana J, Barrioa G, Suelves JM, Correa JF, Domingo-Salvany A. Problematic heroin use incidence trends in Spain. Addiction 2009; 104: 248–255
   PubMed Web of Science ®Google Scholar
• Shorter D, Koster TR. Vaccines in the treatment of substance abuse. Focus 2011; 9: 25–30
   Google Scholar
• Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 2010; 105: 38–48
   PubMed Web of Science ®Google Scholar
• UNODC. World drug report 2010. Author, Vienna 2010
   Google Scholar
• van der Poel A, Rodenburg G, Dijkstra M, Stoele M, van de Mheen D. Trends, motivations and settings of recreational cocaine use by adolescents and young adults in the Netherlands. International Journal of Drug Policy 2009; 20: 143–151
   PubMed Web of Science ®Google Scholar